Bastian Höchst | Onco- Immunology | Best Researcher Award

Dr. Bastian Höchst | Onco- Immunology | Best Researcher Award

Dr. Bastian Höchst,  Institute of Molecular Immunology, MRI, TUM, Germany.

Bastian Höchst is a distinguished molecular immunologist whose career spans groundbreaking research, impactful teaching, and valuable contributions to the scientific community. His academic journey began with a focus on biology and culminated in a doctorate on immune regulation in liver tumors. As a Research Group Leader at the Technical University of Munich, he investigates the complex interplay of immune cells and tissues in acute and chronic inflammation. His pioneering discoveries, such as the mechanisms governing myeloid suppressor cells and immune-regulatory metabolite transfer, have advanced understanding in the field.

Profile

Google Scholar

🌱 Early Academic Pursuits

Bastian Höchst began his academic journey with a passion for understanding the intricate mechanisms of biology. From 1999 to 2005, he pursued his studies in Biology at the University of Bonn and Hamburg, laying the foundation for his future endeavors in molecular immunology. His academic curiosity led him to pursue a doctorate at the Medical School Hannover under the guidance of Prof. Dr. Tim F. Greten. His doctoral research focused on identifying and characterizing myeloid-derived suppressor cells in patients with hepatocellular carcinoma, marking the beginning of his impactful contributions to the field of immunology.

🔬 Professional Endeavors

Currently serving as a Research Group Leader at the Institute of Molecular Immunology, Klinikum rechts der Isar, Technical University of Munich (TUM), Bastian Höchst has dedicated his career to unraveling the complexities of immune regulation. His journey in academia has been marked by significant roles, including his previous tenure as a Research Group Leader at the Institute for Animal Physiology and Immunology, Wissenschaftszentrum Weihenstephan, TUM. Additionally, his postdoctoral fellowship at the Institute of Molecular Medicine and Experimental Immunology at the University of Bonn further honed his expertise in immune mechanisms.

🧪 Contributions and Research Focus

Bastian Höchst’s research delves into immune regulation within acute and chronic inflammatory processes, with a particular focus on tissue-specific mechanisms. He has made groundbreaking discoveries, including elucidating the pathways that govern the generation of myeloid suppressor cells in liver tumors. Furthermore, his innovative work revealed that the intercellular transfer of immune-regulatory metabolites is critical to T-cell effector functions. His research has significantly advanced the understanding of immune responses in disease contexts, bridging gaps in immunological knowledge.

🎓 Teaching and Mentorship

A dedicated educator, Bastian Höchst has been actively involved in teaching since 2010, inspiring students in life sciences programs at TUM. His lectures on topics such as onco-immunology, immune metabolism, and immunotherapy provide invaluable insights to aspiring scientists. Through lab courses on immune cell phenotyping and advanced techniques like spectral flow cytometry, he has empowered students with the skills to explore the complexities of immunology. His teaching contributions extend beyond knowledge dissemination, fostering a generation of critical thinkers and innovators.

📜 Accolades and Recognition

Bastian’s expertise has been recognized through his habilitation and venia legendi for Molecular Immunology, under the mentorship of Prof. Dr. Percy Knolle. His contributions as a scientific reviewer for prestigious journals like Hepatology, Journal of Hepatology, and Frontiers in Immunology further reflect his authority in the field. Additionally, his role in evaluating grant applications for the Deutsche Forschungsgemeinschaft (DFG) underscores his impact on shaping future research initiatives.

🌍 Impact and Influence

Through his research, teaching, and reviews, Bastian Höchst has left an indelible mark on the field of molecular immunology. His work not only uncovers critical mechanisms of immune regulation but also provides pathways for therapeutic advancements in inflammatory and tumor-related conditions. His contributions influence both scientific understanding and practical applications, addressing global challenges in health and disease management.

🌟 Legacy and Future Contributions

Bastian Höchst’s journey is one of passion, discovery, and impact. As he continues to lead groundbreaking research, he sets the stage for a future where immune-based therapies are revolutionized. His legacy lies in his ability to connect fundamental research with real-world applications, inspiring colleagues and mentees alike. With his unwavering commitment to scientific exploration, Bastian Höchst is poised to shape the future of molecular immunology, paving the way for transformative breakthroughs.

Publication

  • A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4+ CD25+ Foxp3+ T cells
    Authors: B. Höchst, L.A. Ormandy, M. Ballmaier, F. Lehner, C. Krüger, M.P. Manns, …
    Year: 2008

 

  • Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor
    Authors: B. Höchst, T. Voigtlaender, L. Ormandy, J. Gamrekelashvili, F. Zhao, …
    Year: 2009

 

  • Functional classification of memory CD8+ T cells by CX3CR1 expression
    Authors: J.P. Böttcher, M. Beyer, F. Meissner, Z. Abdullah, J. Sander, B. Höchst, …
    Year: 2015

 

  • Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells
    Authors: B. Höchst, J. Gamrekelashvili, M.P. Manns, T.F. Greten, F. Korangy
    Year: 2011

 

  • S100A9 a new marker for monocytic human myeloid‐derived suppressor cells
    Authors: F. Zhao, B. Höchst, A. Duffy, J. Gamrekelashvili, S. Fioravanti, M.P. Manns, …
    Year: 2012

 

  • Regulatory myeloid cells paralyze T cells through cell–cell transfer of the metabolite methylglyoxal
    Authors: T. Baumann, A. Dunkel, C. Schmid, S. Schmitt, M. Hiltensperger, K. Lohr, …
    Year: 2020

 

  • Kupffer cell-derived Tnf triggers cholangiocellular tumorigenesis through JNK due to chronic mitochondrial dysfunction and ROS
    Authors: D. Yuan, S. Huang, E. Berger, L. Liu, N. Gross, F. Heinzmann, M. Ringelhan, …
    Year: 2017

 

  • Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC
    Authors: T.F. Greten, L.A. Ormandy, A. Fikuart, B. Höchst, S. Henschen, M. Hörning, …
    Year: 2010

 

Conclusion

Bastian Höchst’s career exemplifies dedication to advancing molecular immunology through innovative research, education, and mentorship. His contributions have shaped the understanding of immune responses in disease contexts, offering hope for novel therapeutic approaches. As he continues to lead impactful research and foster new talent, Bastian Höchst remains a visionary in his field, poised to drive future breakthroughs that bridge science and medicine for the benefit of society.

 

Baoying Huang | Pathogen Biology | Best Researcher Award

Baoying Huang | Pathogen Biology | Best Researcher Award

Ms. Baoying Huang,  National Institute for Viral Disease Control and Prevention, China.

Dr. Baoying Huang, a distinguished professor at the Biotech Center for Viral Disease Emergency, China CDC, has over two decades of experience in combating viral diseases. Her expertise lies in vaccine and antiviral drug development for emerging and re-emerging infectious diseases, including COVID-19, monkeypox, and other human coronaviruses.

 

profile

Scopus

🎓 Education Experience

2008.09–2011.07: Doctor of Medicine, Pathogen Biology,Biotech Center for Viral Disease Emergency, China CDC.2005.09–2008.07: Master of Biology, Pathogen Biology,Biotech Center for Viral Disease Emergency, China CDC. 2001.09–2005.07: Bachelor of Biology,
Life Science Department, Nan Hua University, China.

👩‍🔬 Professional Experience

2020.07–Present:  Professor, China CD ,Focus: Vaccine and antiviral drug R&D for SARS-CoV-2 and poxvirus diseases, including COVID-19 and monkeypox. Key Role: Participated in COVID-19 Emergency Projects for SARS-CoV-2 variant monitoring in China.2015.07–2020.07:  Associate Professor, China CDC. Focus: Vaccine and antiviral drug R&D for emerging infectious diseases like influenza and coronaviruses (SARS-CoV, MERS-CoV).2015.04–2015.06:  Assistant Professor, China CDC. Global Health Support Program: Worked in Sierra Leone to establish Ebola lab systems, improving public health infrastructure.2011.07–2015.07: Assistant Professor, China CDC. Focus: Pathogenic molecular mechanisms of influenza viruses, pseudo-virus applications, and gene-engineered vaccines. 2005.09–2011.07:  Graduate Researcher, IVDC, China CDC. Specialization: Developing universal influenza vaccines for cross-protection against various strains.

🔬 Research Focus

Baoying Huang’s work is dedicated to:Vaccine Development: COVID-19 vaccines (BBIBP-CorV, mRNA vaccines) and pan-orthopoxvirus solutions.Emerging Diseases: Countermeasures for SARS-CoV-2, monkeypox, and other viral threats.Diagnostics: Whole-genome sequencing and real-time PCR for virus detection and monitoring.Therapeutics: Screening novel antivirals targeting viruses like SARS-CoV-2 and monkeypox.Key achievements include:Leading the development of Sinopharm COVID-19 vaccine, later approved by WHO for Emergency Use Listing.Establishing monitoring systems for SARS-CoV-2 variants and assessing their impact on public health measures. Advancing monkeypox vaccine research and identifying promising antiviral compounds against orthopoxviruses.

📚 Publications

  • Title: Molecular architecture of monkeypox mature virus
    • Authors: Hong, Y., Huang, B., Zhang, J., Tan, W., Li, S.
    • Year: 2024

 

  • Title: Vaccinia virus Tiantan strain blocks host antiviral innate immunity and programmed cell death by disrupting gene expression
    • Authors: Wu, C., Zhang, Z., Li, Z., Deng, Y., Tan, W.
    • Year: 2024

 

  • Title: A clinically used anti-human papilloma virus agent (3-hydroxyphthalic anhydride-modified bovine β-lactoglobulin) has a potential for topical application to prevent sexual transmission of monkeypox virus
    • Authors: Sha, Y., Huang, B., Hua, C., Tan, W., Jiang, S.
    • Year: 2024

 

  • Title: Development of a multiplex real-time PCR assay for the simultaneous detection of mpox virus and orthopoxvirus infections
    • Authors: Fan, Z., Xie, Y., Huang, B., Tan, W., Guo, F.
    • Year: 2024

 

  • Title: Accurate determination of the whole genome sequencing and open reading frames composition of non-replicating Tiantan strain of vaccinia virus based on novel long read sequencing platform
    • Authors: Zhang, Z., Wu, C., Li, H., Huang, B., Tan, W.
    • Year: 2024

 

  • Title: Characterization of whole genomes from recently emerging Mpox cases in several regions of China, 2023
    • Authors: Wu, C., Cui, L., Pan, Y., Wang, Q., Tan, W.
    • Year: 2024

 

  • Title: Intranasal immunization with single-dose vaccine based on recombinant influenza virus H1N1 expressing the extracellular domain of respiratory syncytial virus G protein induces robust immunity and protection in mice
    • Authors: Han, R., Wang, D., Wang, T., Huang, B., Tan, W.
    • Year: 2024

 

  • Title: Rapid identification of full-length genome and tracing variations of monkeypox virus in clinical specimens based on mNGS and amplicon sequencing
    • Authors: Wu, C., A, R., Ye, S., Lu, J., Tan, W.
    • Year: 2024

 

  • Title: Long-lasting humoral and cellular memory immunity to vaccinia virus Tiantan provides pre-existing immunity against mpox virus in Chinese population
    • Authors: Li, M., Guo, Y., Deng, Y., Gao, G.F., Liu, J.
    • Year: 2024

 

  • Title: Identification of the VP37 pocket of monkeypox virus as a promising target for pan-orthopoxvirus inhibitors through virtual screening and antiviral assays
    • Authors: Huo, S., Wu, L., Huang, B., Xu, Z., Tan, W.
    • Year: 2024

 

Conclusion

Dr. Huang’s career exemplifies unwavering dedication to improving public health through innovation in vaccine development, antiviral research, and diagnostic technologies. Her contributions to tackling global health challenges, such as the COVID-19 pandemic and monkeypox outbreaks, have significantly impacted infectious disease prevention and control worldwide. As viruses continue to evolve, her pioneering work remains a cornerstone in safeguarding global health.